Targeted enzymes destroy virus RNA

A research team led by the Technical University of Munich (TUM) has successfully used specific enzymes to destroy the genetic information of SARS-CoV-2 directly after the virus penetrates the cell. The findings could serve as the basis for a therapy to treat COVID-19.

Our genome contains building instructions for proteins and other molecules. In order for these to be produced by the cell, a kind of transcript of these building instructions must first be created, which takes the form of so-called RNA molecules. The transcript is recognized and implemented by the cells.

"However, there is also a mechanism that can very specifically destroy this RNA, which takes place in all human cells as part of gene regulation," explains Dr. Thomas Michler, who led the current study at the Institute of Virology of TUM and Helmholtz Zentrum München. "It is the so-called RNA interference."

In this process, short pieces of RNA are formed in the cell, called siRNA (small interfering RNA). These segments can bond to specific spots in an RNA molecule. Together with proteins, the siRNA forms what is called the RNA-Induced Silencing Complex (RISC), an enzyme which then cuts the target RNA.

Virus introduces RNA into cell

"Efforts have been made for quite some time now to make therapeutic use of this mechanism," says Ulrike Protzer, head of the TUM Institute of Virology. "A lot of progress has been made in this area over the last few years. Among other things, it is now possible to stabilize siRNA by chemical modifications so that it is not broken down so quickly in cells."

In SARS-CoV-2, there are two targets for RNA interference: First, the genome of the virus consists of RNA, which is introduced into the infected cell and contains the blueprint for new viruses. Second, so-called subgenomic RNA molecules are formed, which instruct the host cell to produce viral proteins.

Start of the replication cycle as the most effective point of attack

The research team primarily wanted to find out which of the virus RNA structures can be best attacked and at which step of the replication cycle treatment should take place. "Our main finding is that the RNA interference is most effective when the virus has just penetrated into the cell," says Shubhankar Ambike, one of the study's first authors. Here, siRNAs that selectively target the viral genome were superior to other siRNAs that target the subgenomic RNA molecules.

Working together with colleagues at Ludwig Maximilian University of Munich and German Research Center for Environmental Health Helmholtz Zentrum München, the researchers also performed experiments on human lung tissue which they had infected with SARS-CoV-2. The experiments confirmed their results. In a follow-up project, the researchers are now planning to develop a method which can be used to bring the active ingredient into the lung in the most effective possible manner. The results could then serve as the basis for therapies to treat other viral respiratory diseases.

Ambike S, Cheng CC, Feuerherd M, Velkov S, Baldassi D, Afridi SQ, Porras-Gonzalez D, Wei X, Hagen P, Kneidinger N, Stoleriu MG, Grass V, Burgstaller G, Pichlmair A, Merkel OM, Ko C, Michler T.
Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.
Nucleic Acids Res. 2022 Jan 11;50(1):333-349. doi: 10.1093/nar/gkab1248

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...